Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology

Despite guideline recommendations and available evidence, implementation of treatment in heart failure (HF) is poor. The majority of patients are not prescribed drugs at target doses that have been proven to positively impact morbidity and mortality. Among others, tolerability issues related to low blood pressure, heart rate, impaired renal function or hyperkalaemia are responsible. Chronic kidney disease plays an important role as it affects up to 50% of patients with HF. Also, dynamic changes in estimated glomerular filtration rate may occur during the course of HF, resulting in inappropriate dose reduction or even discontinuation of decongestive or neurohormonal modulating therapy in clinical practice. As patients with HF are rarely naïve to pharmacologic therapies, the challenge is to adequately prioritize or select the most appropriate up‐titration schedule according to patient profile. In this consensus document, we identified nine patient profiles that may be relevant for treatment implementation in HF patients with a reduced ejection fraction. These profiles take into account heart rate (<60 bpm or >70 bpm), the presence of atrial fibrillation, symptomatic low blood pressure, estimated glomerular filtration rate (<30 or >30 mL/min/1.73 m2) or hyperkalaemia. The pre‐discharge patient, frequently still congestive, is also addressed. A personalized approach, adjusting guideline‐directed medical therapy to patient profile, may allow to achieve a better and more comprehensive therapy for each individual patient than the more traditional, forced titration of each drug class before initiating treatment with the next.

[1]  Deepak L. Bhatt,et al.  Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. , 2020, The New England journal of medicine.

[2]  P. Ponikowski,et al.  Heart Failure Association of the European Society of Cardiology update on sodium–glucose co‐transporter 2 inhibitors in heart failure , 2020, European journal of heart failure.

[3]  J. McMurray,et al.  Dapagliflozin in Patients with Chronic Kidney Disease. , 2020, The New England journal of medicine.

[4]  Akshay S. Desai,et al.  Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction , 2020, Circulation.

[5]  P. Ponikowski,et al.  Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. , 2020, The New England journal of medicine.

[6]  A. Strömberg,et al.  Lower socioeconomic status predicts higher mortality and morbidity in patients with heart failure , 2020, Heart.

[7]  J. Butler,et al.  Pathogenesis of chronic heart failure: cardiovascular aging, risk factors, comorbidities, and disease modifiers , 2020, Heart Failure Reviews.

[8]  W. Heggermont,et al.  Clinical inertia in the treatment of heart failure: a major issue to tackle , 2020, Heart Failure Reviews.

[9]  N. Thilly,et al.  Sustained adherence to ESC guideline‐recommended medications is associated with lower long‐term mortality in heart failure and reduced ejection fraction: Insights from the EPICAL2 cohort , 2020, Journal of clinical pharmacy and therapeutics.

[10]  M. Metra,et al.  Guideline‐directed medical therapy for heart failure does not exist: a non‐judgmental framework for describing the level of adherence to evidence‐based drug treatments for patients with a reduced ejection fraction , 2020, European journal of heart failure.

[11]  G. Filippatos,et al.  Unravelling the interplay between hyperkalaemia, renin–angiotensin–aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC‐HFA‐EORP Heart Failure Long‐Term Registry , 2020, European journal of heart failure.

[12]  J. Bauersachs,et al.  Heart rate control in heart failure with reduced ejection fraction: the bright and the dark side of the moon , 2020, European journal of heart failure.

[13]  H. Heerspink,et al.  Randomized, double‐blind, placebo‐controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA‐RESPONSE‐AHF) , 2020, European journal of heart failure.

[14]  A. Mebazaa,et al.  Evaluation of kidney function throughout the heart failure trajectory – a position statement from the Heart Failure Association of the European Society of Cardiology , 2020, European journal of heart failure.

[15]  L. Lund,et al.  Hyperkalemia in heart failure patients in Spain and its impact on guidelines and recommendations: ESC-EORP-HFA Heart Failure Long-Term Registry. , 2020, Revista espanola de cardiologia.

[16]  G. Filippatos,et al.  Sex‐ and age‐related differences in the management and outcomes of chronic heart failure: an analysis of patients from the ESC HFA EORP Heart Failure Long‐Term Registry , 2019, European journal of heart failure.

[17]  P. Ponikowski,et al.  European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose‐lowering drugs in patients with heart failure , 2019, European journal of heart failure.

[18]  P. Ponikowski,et al.  Acute heart failure congestion and perfusion status – impact of the clinical classification on in‐hospital and long‐term outcomes; insights from the ESC‐EORP‐HFA Heart Failure Long‐Term Registry , 2019, European journal of heart failure.

[19]  G. Rosano,et al.  Association between beta‐blocker use and mortality/morbidity in older patients with heart failure with reduced ejection fraction. A propensity score‐matched analysis from the Swedish Heart Failure Registry , 2019, European Journal of Heart Failure.

[20]  P. Ponikowski,et al.  Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology , 2019, European journal of heart failure.

[21]  S. Anker,et al.  Pharmacy‐based interdisciplinary intervention for patients with chronic heart failure: results of the PHARM‐CHF randomized controlled trial , 2019, European journal of heart failure.

[22]  E. Lonn,et al.  Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study , 2019, European journal of heart failure.

[23]  Thomas Thum,et al.  The continuous heart failure spectrum: moving beyond an ejection fraction classification. , 2019, European heart journal.

[24]  P. Ponikowski,et al.  Physicians' guideline adherence is associated with long‐term heart failure mortality in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry , 2019, European journal of heart failure.

[25]  E. Braunwald,et al.  Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure , 2019, The New England journal of medicine.

[26]  Deepak L. Bhatt,et al.  Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes , 2019, The New England journal of medicine.

[27]  Marc P. Bonaca,et al.  SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials , 2019, The Lancet.

[28]  G. Filippatos,et al.  The use of diuretics in heart failure with congestion — a position statement from the Heart Failure Association of the European Society of Cardiology , 2019, European journal of heart failure.

[29]  L. Lund,et al.  Association between renin–angiotensin system inhibitor use and mortality/morbidity in elderly patients with heart failure with reduced ejection fraction: a prospective propensity score-matched cohort study , 2018, European heart journal.

[30]  B. Zinman,et al.  Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial. , 2018, Journal of the American Society of Nephrology : JASN.

[31]  Thomas Kahan,et al.  [2018 ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH)]. , 2018, Giornale italiano di cardiologia.

[32]  L. Lund,et al.  Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry , 2018, European journal of heart failure.

[33]  P. Ponikowski,et al.  Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology , 2018, European heart journal. Cardiovascular pharmacotherapy.

[34]  K. Swedberg,et al.  Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: a network meta‐analysis , 2018, European journal of heart failure.

[35]  L. Lund,et al.  Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists , 2018, European journal of heart failure.

[36]  Akshay S. Desai,et al.  Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure. , 2018, JACC. Heart failure.

[37]  G. Filippatos,et al.  Ups and downs in heart failure: the case of proteomics , 2018, European journal of heart failure.

[38]  A. Rigby,et al.  Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials , 2018, European heart journal.

[39]  Roberto Ferrari,et al.  Epidemiology and one‐year outcomes in patients with chronic heart failure and preserved, mid‐range and reduced ejection fraction: an analysis of the ESC Heart Failure Long‐Term Registry , 2017, European journal of heart failure.

[40]  L. Lund,et al.  Association between enrolment in a heart failure quality registry and subsequent mortality—a nationwide cohort study , 2017, European journal of heart failure.

[41]  L. Lund,et al.  Association between demographic, organizational, clinical, and socio‐economic characteristics and underutilization of cardiac resynchronization therapy: results from the Swedish Heart Failure Registry , 2017, European journal of heart failure.

[42]  Volkmar Falk,et al.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure , 2016, Revista espanola de cardiologia.

[43]  G. Filippatos,et al.  Urine proteome analysis in heart failure with reduced ejection fraction complicated by chronic kidney disease: feasibility, and clinical and pathogenetic correlates , 2016, European journal of heart failure.

[44]  P. Ponikowski,et al.  Non‐adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT , 2016, European journal of heart failure.

[45]  C. Angermann,et al.  Nurse‐coordinated collaborative disease management improves the quality of guideline‐recommended heart failure therapy, patient‐reported outcomes, and left ventricular remodelling , 2015, European journal of heart failure.

[46]  P. Kirchhof,et al.  Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis , 2014, The Lancet.

[47]  P. Ponikowski,et al.  Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Long‐Term Registry , 2013, European journal of heart failure.

[48]  Akshay S. Desai,et al.  Influence of baseline and worsening renal function on efficacy of spironolactone in patients With severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study). , 2012, Journal of the American College of Cardiology.

[49]  J. Calvin,et al.  Adherence to evidence-based guidelines for heart failure in physicians and their patients: lessons from the Heart Failure Adherence Retention Trial (HART). , 2012, Congestive heart failure.

[50]  Dwight Reynolds,et al.  Incremental Reduction in Risk of Death Associated With Use of Guideline-Recommended Therapies in Patients With Heart Failure: A Nested Case-Control Analysis of IMPROVE HF , 2012, Journal of the American Heart Association.

[51]  M. Volterrani,et al.  Effect of Carvedilol, Ivabradine or their combination on exercise capacity in patients with Heart Failure (the CARVIVA HF trial). , 2011, International journal of cardiology.

[52]  Bertram Pitt,et al.  Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial , 2011, European heart journal.

[53]  Michael Böhm,et al.  Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study , 2010, The Lancet.

[54]  J. Rumsfeld,et al.  Treatment and Risk in Heart Failure: Gaps in Evidence or Quality? , 2010, Circulation. Cardiovascular quality and outcomes.

[55]  K. Dickstein,et al.  Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial , 2009, The Lancet.

[56]  J. Rouleau,et al.  Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. , 2004, Journal of the American College of Cardiology.

[57]  P. Armstrong,et al.  Renal Insufficiency and Heart Failure: Prognostic and Therapeutic Implications From a Prospective Cohort Study , 2004, Circulation.

[58]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.